A phase I/II randomized trial using GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) vaccine in combination with CCL21 in stage IV lung adenocarcinoma: Preliminary results.
Year: 2013
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Jhanelle Elaine Gray, Alberto Chiappori, Charles C. Williams, Mary Colleen Pinder, Eric B. Haura, Jongphil Kim, Germaine Gonzalez, David Noyes, Scott J. Antonia
Institution: Moffitt Cancer Center
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2603537333